Bone Biologics Announces Closing of $2.0 Million Public Offering

Core Viewpoint - Bone Biologics Corporation has successfully closed a public offering, raising approximately $2.0 million through the sale of 781,251 shares of common stock and accompanying warrants, aimed at funding clinical trials and other corporate purposes [1][2]. Group 1: Offering Details - The public offering consisted of 781,251 shares of common stock priced at $2.56 per share, along with warrants to purchase an equal number of shares at an exercise price of $2.43, which are exercisable immediately and will expire in five years [1][2]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for funding clinical trials, maintaining and extending the patent portfolio, and for working capital and other general corporate purposes [2]. Group 3: Company Background - Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is developing a bone graft substitute product based on preclinical research of the Nell-1 protein [4].